Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc Share Price

$25.4 1.3  5.4%

Last Trade - 30/03/20

Market Cap £695.1m
Enterprise Value £731.9m
Revenue £n/a
Position in Universe 2195th / 6323
Bullish
Bearish
Unlock BDTX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BDTX Revenue Unlock BDTX Revenue

Net Income

BDTX Net Income Unlock BDTX Revenue

Normalised EPS

BDTX Normalised EPS Unlock BDTX Revenue

PE Ratio Range

BDTX PE Ratio Range Unlock BDTX Revenue

Dividend Yield Range

BDTX Dividend Yield Range Unlock BDTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BDTX EPS Forecasts Unlock BDTX Revenue
Profile Summary

Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. The Company has designed its lead product candidate, BDTX-189, to block the function of an undrugged family of oncogenic proteins defined by mutations which occur across a range of tumor types, and which affect both the epidermal growth factor receptor (EGFR) and the tyrosine-protein kinase ErbB-2, or HER2.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated December 29, 2014
No. of Shareholders: 72
No. of Employees: 32
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 35,910,705
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BDTX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to BDTX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.